02/24/2025, 05:16 AM UTC
Exact Sciences：强劲的第四季度业绩揭示潜在拐点迹象Exact Sciences: A Strong Q4 Reveals Signs Of A Potential Inflection Point
1. Exact Sciences报告了强劲的第四季度收入增长，但由于Thrive收购的8.38亿美元减值损失，每股收益未达标。2. 尽管市场反应负面，Exact的核心业务显示出动力，Cologuard需求强劲，现金储备稳健，达到10.4亿美元。3. 公司对2025年的收入增长设定了雄心勃勃的目标，并预计新产品推出将推动增长，旨在实现持续盈利和长期价值。1. Exact Sciences reported strong Q4 revenue growth, but missed EPS due to an $838M impairment charge from the Thrive acquisition. 2. Despite the negative market reaction, Exact's core business shows momentum with strong demand for Cologuard and a solid cash position of $1.04B. 3. The company has ambitious 2025 revenue guidance and expects new product launches to drive growth, aiming for sustained profitability and long-term value.---
本文由大语言模型（LLM）生成，旨在为读者提供半导体新闻内容的知识扩展（Beta）。
